{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:10:40Z","timestamp":1783728640637,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2026852"],"award-info":[{"award-number":["GNT2026852"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100025520","name":"Medical Research Future Fund","doi-asserted-by":"publisher","award":["APP 1200314"],"award-info":[{"award-number":["APP 1200314"]}],"id":[{"id":"10.13039\/501100025520","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.hlc.2025.06.1019","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T19:49:33Z","timestamp":1756496973000},"page":"1069-1077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Diabetes and Cardiometabolic Care, Pharmacotherapy, and Patient Outcomes in Two Regional Aboriginal Primary Care Health Centres: Lessons to be Learnt"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7596-6980","authenticated-orcid":false,"given":"Annabelle G.","family":"Hayes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odette","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8086-2449","authenticated-orcid":false,"given":"Chinmay S.","family":"Marathe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2026-3671","authenticated-orcid":false,"given":"David","family":"Jesudason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2025.06.1019_bib1","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1001\/jama.2023.22276","article-title":"Here's what to know about cardiovascular-kidney-metabolic syndrome, newly defined by the AHA","volume":"330","author":"Larkin","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.hlc.2025.06.1019_bib2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.5694\/mja2.50529","article-title":"Cardiovascular disease risk assessment for Aboriginal and Torres Strait Islander adults aged under 35 years: a consensus statement","volume":"212","author":"Agostino","year":"2020","journal-title":"Med J Aust"},{"key":"10.1016\/j.hlc.2025.06.1019_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-059716","article-title":"Prevalence and incidence of diabetes among Aboriginal people in remote communities of the Northern Territory, Australia: a retrospective, longitudinal data-linkage study","volume":"12","author":"Hare","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.hlc.2025.06.1019_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195030","article-title":"Mortality in a cohort of remote-living aboriginal Australians and associated factors","volume":"13","author":"Hyde","year":"2018","journal-title":"PLOS One"},{"key":"10.1016\/j.hlc.2025.06.1019_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5694\/mja2.13002","article-title":"Emerging diabetes and metabolic conditions among Aboriginal and Torres Strait Islander young people","volume":"210","author":"Titmuss","year":"2019","journal-title":"Med J Aust"},{"key":"10.1016\/j.hlc.2025.06.1019_bib7","author":"Gibson"},{"key":"10.1016\/j.hlc.2025.06.1019_bib8","author":"Taylor"},{"key":"10.1016\/j.hlc.2025.06.1019_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0276396","article-title":"Effective primary care management of type 2 diabetes for indigenous populations: a systematic review","volume":"17","author":"Chopra","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.hlc.2025.06.1019_bib14","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.hlc.2025.06.1019_bib15","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/ejhf.1328","article-title":"Empagliflozin directly improves diastolic function in human heart failure","volume":"20","author":"Pabel","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.hlc.2025.06.1019_bib16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hlc.2025.06.1019_bib17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.hlc.2025.06.1019_bib18","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"10193","key":"10.1016\/j.hlc.2025.06.1019_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.hlc.2025.06.1019_bib20","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/dom.13658","article-title":"Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups","volume":"21","author":"Fuechtenbusch","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.hlc.2025.06.1019_bib21","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.hlc.2025.06.1019_bib22","doi-asserted-by":"crossref","first-page":"422","DOI":"10.5694\/mja2.51482","article-title":"Management of type 2 diabetes in young adults aged 18\u201330 years: ADS\/ADEA\/APEG consensus statement","volume":"216","author":"Wong","year":"2022","journal-title":"Med J Aust"},{"key":"10.1016\/j.hlc.2025.06.1019_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12961-024-01121-x","article-title":"A rapid review to inform the policy and practice for the implementation of chronic disease prevention and management programs for Aboriginal and Torres Strait Islander people in primary care","volume":"22","author":"Yadav","year":"2024","journal-title":"Health Res Policy Syst"},{"key":"10.1016\/j.hlc.2025.06.1019_bib25","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/imj.13123","article-title":"Management of diabetes in Indigenous communities: lessons from the Australian Aboriginal population","volume":"46","author":"Nguyen","year":"2016","journal-title":"Intern Med J"},{"key":"10.1016\/j.hlc.2025.06.1019_bib27","doi-asserted-by":"crossref","first-page":"494","DOI":"10.5694\/j.1326-5377.2007.tb01020.x","article-title":"Diabetes in Indigenous Australians: possible ways forward","volume":"186","author":"O'Dea","year":"2007","journal-title":"Med J Aust"},{"key":"10.1016\/j.hlc.2025.06.1019_bib28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12913-015-0695-5","article-title":"Community health workers improve diabetes care in remote Australian Indigenous communities: results of a pragmatic cluster randomized controlled trial","volume":"15","author":"McDermott","year":"2015","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.hlc.2025.06.1019_bib29","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/ajr.12062","article-title":"Issues that impact on Aboriginal Health Workers' and Registered Nurses' provision of diabetes health care in rural and remote health settings","volume":"21","author":"King","year":"2013","journal-title":"Aust J Rural Health"},{"key":"10.1016\/j.hlc.2025.06.1019_bib30","series-title":"National Evidence-Based Guideline on Secondary Prevention of Cardiovascular Disease in Type 2 Diabetes: Canberra","first-page":"2","year":"2015"},{"key":"10.1016\/j.hlc.2025.06.1019_bib31","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00125-018-4544-z","article-title":"Impact of age at diagnosis and duration of Type 2 diabetes on mortality in Australia 1997\u20132011","volume":"61","author":"Huo","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.hlc.2025.06.1019_bib32","author":"Fischer-Claussen"},{"key":"10.1016\/j.hlc.2025.06.1019_bib34","doi-asserted-by":"crossref","DOI":"10.1071\/PY23124","article-title":"Supporting best practice in the management of chronic diseases in primary health care settings: a scoping review of training programs for Indigenous Health Workers and Practitioners","volume":"30","author":"Pearson","year":"2024","journal-title":"Aust J Prim Health"},{"key":"10.1016\/j.hlc.2025.06.1019_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0305472","article-title":"Translation of culturally and contextually informed diabetes training for Aboriginal primary health care providers on Aboriginal client outcomes: protocol of a cluster randomized crossover trial of effectiveness","volume":"19","author":"Pearson","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.hlc.2025.06.1019_bib36","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/ajr.13032","article-title":"Pharmaceutical management of Type 2 diabetes among Indigenous Australians living in urban or rural locations: a comparative study using a national general practice database","volume":"31","author":"Pink","year":"2023","journal-title":"Aust J Rural Health"},{"key":"10.1016\/j.hlc.2025.06.1019_bib37","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1111\/dom.15196","article-title":"Contemporary trends in the utilization of second-line pharmacological therapies for Type 2 diabetes in the United States and the United Kingdom","volume":"25","author":"Abrahami","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.hlc.2025.06.1019_bib38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.5694\/j.1326-5377.2001.tb143507.x","article-title":"Regional variation in the incidence of end-stage renal disease in Indigenous Australians","volume":"175","author":"Cass","year":"2001","journal-title":"Med J Aust"},{"key":"10.1016\/j.hlc.2025.06.1019_bib39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.06.1019_bib40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.orcp.2025.04.003","article-title":"Interventions to prevent or treat obesity in adult Indigenous Australians: a systematic review","volume":"19","author":"Lan","year":"2025","journal-title":"Obes Res Clin Pract"},{"key":"10.1016\/j.hlc.2025.06.1019_bib41","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.hlc.2025.06.1019_bib42","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/hpja.864","article-title":"Priority setting: development of the South Australian Aboriginal Chronic Disease Consortium RoadMap for Action","volume":"35","author":"Morey","year":"2024","journal-title":"Health Promot J Austr"},{"key":"10.1016\/j.hlc.2025.06.1019_bib43","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s13063-024-08267-7","article-title":"Can flash glucose monitoring improve glucose management for Aboriginal and Torres Strait Islander peoples with Type 2 diabetes? A protocol for a randomised controlled trial","volume":"25","author":"Hachem","year":"2024","journal-title":"Trials"},{"issue":"Suppl 1","key":"10.1016\/j.hlc.2025.06.1019_bib44","first-page":"S73","article-title":"8. Pharmacologic approaches to glycemic treatment: standards of medical care in Diabetes-2018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.hlc.2025.06.1019_bib45","first-page":"S1","article-title":"Introduction: standards of medical care in diabetes\u20142020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.hlc.2025.06.1019_bib46","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"issue":"4s","key":"10.1016\/j.hlc.2025.06.1019_bib47","first-page":"S1","article-title":"Clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","year":"2020","journal-title":"Kidney Int"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950625015094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950625015094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:03:22Z","timestamp":1772888602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950625015094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1443950625015094"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2025.06.1019","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetes and Cardiometabolic Care, Pharmacotherapy, and Patient Outcomes in Two Regional Aboriginal Primary Care Health Centres: Lessons to be Learnt","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2025.06.1019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ).","name":"copyright","label":"Copyright"}]}}